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Abstract: Tumors of salivary glands are uncommon and comprise of about 2%–4% of all head and neck tumors. About 75%–80% of 
these tumors are benign and include pleomorphic adenoma, monomorphic adenoma, oncocytoma, and papillary cystadenoma lympho-
matosum. Mucoepidermoid carcinoma is the most common malignant tumor of salivary glands, representing 5–10% of all salivary 
gland tumors. Although known to be metastatic to local lymph nodes, distant metastases are rare (especially, with low and intermediate 
grade tumors). Histologic grade and the expression of various mucin glycoproteins are useful prognostic indicators. We present a case of 
mucoepidermoid carcinoma of parotid gland origin with distant metastases which is an uncommon occurrence with intermediate grade 
tumors. Also, this is the first reported case of humoral hypercalcemia of malignancy secondary to mucoepidermoid carcinoma.
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case
A  74  year  old  man  presented  with  an  enlarging 
painless left posterior parotid mass over a 4 month 
period. The patient had a history of coronary artery 
disease,  acute  pancreatitis,  and  benign  prostate 
enlargement. He denied weight loss, fever, chills, 
dysphagia, dysphonia, facial numbness or paresis. 
The physical exam revealed a 3 × 4 cm left poste-
rior rubbery fixed mass at the angle of the mandible 
without palpable lymphadenopathy. The neurologi-
cal exam was   negative for involvement of the cra-
nial nerves.
Magnetic resonance imaging (MRI) of the neck 
was significant for a 3 × 2.3 × 2.7 cm left parotid 
mass involving the superficial and deep lobes of the 
gland with slight displacement of the submandibu-
lar vein, and without regional or distant lymphade-
nopathy. A fine needle aspiration (FNA) biopsy of 
the mass revealed epidermoid and mucous secret-
ing cells. Subsequently, the patient had a deep lobe 
parotidectomy followed by immediate reconstruc-
tion with a sternocleidomastoid flap. The pathol-
ogy  report  was  diagnostic  of  an  intermediate 
grade  mucoepidermoid  carcinoma  of  the  salivary 
gland  with  clear  margins;  the  clinical  stage  was 
pT2pN0pMx.
The patient received adjuvant radiotherapy deliv-
ered 5 days a week for 7 weeks at 180cGy per day. 
The patient was followed at the oncology clinic at 
3 month intervals. Regular imaging with CT scan of 
the neck was done every 6 months without evidence 
of recurrence.
Thirty  months  postoperatively,  the  patient  pre-
sented to the hospital with severe generalized weak-
ness, decreased appetite, weight loss, and change in 
mental  status.  Laboratory  evaluation  revealed  cor-
rected calcium of 15.1 mg/dl, creatinine of 1.9 mg/dl, 
intact PTH of 3pg/ml, PTHrp of 11.1pg/ml, without 
monoclonal protein on immunofixation.
CT scan of the head, chest, abdomen and pelvis 
revealed a large heterogeneous mass in the left lobe of 
the liver measuring approximately 10.6 cm × 9.9 cm, 
with multiple smaller satellite lesions throughout the 
liver measuring up to 1.7 cm. A 1.9 × 1.6 cm right 
lower  para  esophageal  lymph  node  adjacent  to  a 
hiatal hernia and a 1 cm right para tracheal lymph 
node were also found.
A CT guided needle biopsy of the liver mass was 
histologically similar to the parotid mass with the 
same immunohistochemical features including pos-
itive GCDFP-15. The transbronchial needle biopsy 
of the right para tracheal lymph node was negative 
for  malignant  cells.  The  patient  was  discharged 
after treatment with intra-venous pamidronate and 
fluids.  The  corrected  calcium  at  discharge  was 
11.5 mg/dl.
The patient’s symptoms as well as the hypercal-
cemia resolved after 4 cycles of chemotherapy with 
Figure 1. MrI of the neck done on the initial presentation showing a 3 cm 
by 2.3 cm by 2.7 cm left parotid mass, involving the superficial and deep 
lobes of the left parotid gland.
Figure 2. CT abdomen showing a 10.6 cm by 9.8 cm heterogenous mass 
in the liver.
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7th cycle of carboplatin, the patient developed throm-
bocytopenia  necessitating  withdrawal  of  the  drug. 
Eight weeks later the patient was readmitted to the 
hospital for malignant hypercalcemia with corrected 
calcium of 16.4 mg/dl. A CT scan of the abdomen and 
pelvis revealed further progression of the liver mass 
to 14.2 × 13 cm. After discussion with the patient’s 
family,  it  was  decided  to  discontinue  any  further 
  disease-directed  treatment  and  the  patient  was  put 
under hospice care.
Discussion
Mucoepidermoid carcinoma is one of the most com-
mon malignant tumors of salivary glands, represent-
ing 5%–10% of all salivary gland tumors. However, 
these tumors are also known to occur in lips, tongue, 
and buccal mucosa.1 Although known  to be meta-
static to local lymph nodes, distant metastases are 
rare  (especially,  with  low  and  intermediate  grade 
tumors).
Histologic grading has been shown to be of prog-
nostic  significance  in  these  tumors,  but  there  has 
been a lack of consensus about a standard grading 
system. Nevertheless, grading is based on various 
factors including proportion of different cell types, 
nuclear  to  cytoplasmic  ratio,  presence  of  multiple 
nuclei,  hyperchromatism,  mitotic  rate,  anaplasia 
characterized by cellular and nuclear pleomorphism, 
proportion of cystic spaces compared to solid areas, 
necrosis, neural invasion, vascular infiltration, and 
tumor size.2,3 Among these, the features that corre-
late with poor outcomes are 4 or more mitotic figures 
per ten high power fields, necrosis, anaplasia, neu-
ral involvement, and a cystic component of less than 
twenty percent.
The histologic grade usually correlates well with 
prognosis, as non-high grade tumors rarely metasta-
size. In the rare instances when low and intermedi-
ate grade tumors metastasize, they are more likely to 
be of minor salivary gland origin.4,5 Our case is an 
atypical one since intermediate grade MEC’s origi-
nating from parotid glands uncommonly metastasize 
distantly.
The  diagnosis  of  metastatic  disease  from  sali-
vary  glands  was  based  on  expression  of  GCD-
FP-15 in both the primary tumor and the metastatic 
lesions.  GCDPF-15  is  a  marker  of  glandular 
Figure 3. CT guided FNA biopsy specimen showing poorly differentiated 
squamous carcinoma with rare neuroendocrine differentiation.
Figure 4. CT guided FNA cytology smears positive for poorly differenti-
ated squamous carcinoma with rare neuroendocrine differentiation.
carboplatin  (AUC5)  and  paclitaxel  (175  mg/m2) 
given every three weeks. A PET scan confirmed a 
partial response to the chemotherapy but revealed a 
level two 1 cm right cervical lymph node (SUV 4.3) 
that had not been seen on previous CT scans. The 
right para tracheal and para esophageal lymph nodes 
were unchanged and were not FDG avid. The liver 
mass decreased to 7 × 8.5 cm. Another CT scan of 
the abdomen and pelvis after the 6th cycle of che-
motherapy revealed a decrease in the liver mass to 
6.8 × 6.1 cm.
After the 6th cycle of chemotherapy, the patient 
developed  grade  IV  peripheral  neuropathy  and 
as  a  result,  paclitaxel  was  discontinued. After  the 
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  differentiation and is associated with apocrine secre-
tion.    Immunohistchemically  this  glycoprotein  has 
been identified in apocrine cells of breast and skin, 
parotid glands, and sub-mucosal bronchial glands.6 
Among the tumors of salivary gland origin, 76% of 
the benign lesions vs. 28% of the malignant ones 
stained positively for the protein. In another study, 
GCDFP-15 was found to be positive in 40% cases of 
  mucoepidermoid carcinoma.7
Evaluating the origin of meastatic disease could be 
difficult and confusing in many cases because of the 
presence of concomitant cancers. In our case, although 
the origin of metastatic disease was considered to be 
of the salivary gland origin, the chance of having a 
second  malignancy  could  not  be  completely  ruled 
out. Mucke et al. have suggested the role of endos-
copy and bronchoscopy at the time of initial staging 
of salivary gland tumors.8 The role of bronchoscopy 
was significant in the detection of concomitant malig-
nancies. 6 out of 95 patients were identified to have 
malignancies in the lung with 4 being carcinomas of 
lung and 2 represented metastases from the salivary 
gland tumors.
The  expression  of  mucin  glycoproteins  on 
mucoepidermoid  carcinoma  has  been  evaluated  in 
various studies. MUC5 AC in high grade MEC’s is 
helpful in differentiating them from squamous cell 
carcinomas, MUC4 is associated with better tumor 
differentiation and better prognosis, and the expres-
sion of MUC1 is related to tumor progression and 
worse prognosis.
Hypercalcemia has been reported to occur in 20–30 
percent of cases of cancer at some point in the disease. 
In 80% of these, it is mediated by the secretion of 
PTHrP by the tumor cells and is termed as Humoral 
Hypercalcemia of Malignancy (HHM).9 It is associ-
ated with various squamous cell, endometrial, breast 
and renal cancers among others. To our knowledge, 
this is the first reported case of humoral hyeprcalce-
mia associated with mucoepidermoid carcinoma. The 
development of hypercalcemia in cancer patients sig-
nifies a pre-terminal event in the disease course, as 
it was in our patient. According to one study, 50% 
of  cancer  patients  with  hypercalcemia  died  within 
30 days of developing high calcium levels.10
This  case  emphasizes  the  importance  of  the 
development of a standard grading system to bet-
ter  characterize  mucoepidermoid  carcinomas. The 
importance of various immunohistochemical mark-
ers needs to be better defined, and further studies are 
needed to evaluate their diagnostic and prognostic 
significance.
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